Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Theralase TechnologiesTLTFF -1.37%45 Debt-to-Equity is 0.22 as of Mar. 2026, which is 47% above its 10-year median of 0.15. GuruFocus rates TLTFF with a GF Score™ of 45/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 704 Medical Devices & Instruments companies, Theralase Technologies ranks better than 51.14% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Theralase Technologies's Debt-to-Equity or its related term are showing as below:
TLTFF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.15 Max: 0.29
Current: 0.22
During the past 13 years, the highest Debt-to-Equity Ratio of Theralase Technologies was 0.29. The lowest was 0.01. And the median was 0.15.
TLTFF's Debt-to-Equity is ranked better than 51.14% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs TLTFF: 0.22
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Theralase Technologies Debt-to-Equity Related Terms
Theralase Technologies Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Theralase Technologies's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Theralase Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theralase Technologies (TLTFF) has a Debt-to-Equity of 0.22 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Theralase Technologies and its competitors. This is 47% above median its historical median of 0.15. Over the past decade, Theralase Technologies' Debt-to-Equity has ranged from 0.01 to 0.29. According to the industry distribution chart, Theralase Technologies ranks #344 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 48.9%.
Is Theralase Technologies' Debt-to-Equity too high?
Theralase Technologies' current Debt-to-Equity of 0.22 is 47% above median its 10-year median of 0.15. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.29. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Theralase Technologies' value of 0.22 is 4.3% below this industry median. Based on the distribution chart, Theralase Technologies ranks #344 out of 704 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Theralase Technologies has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Theralase Technologies ranks #344 out of 704 companies for Debt-to-Equity. This puts Theralase Technologies in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Theralase Technologies' value of 0.22 is 4.3% below this benchmark. Historically, Theralase Technologies' own Debt-to-Equity has ranged from 0.01 to 0.29 over the past decade. While the company's 10-year median is 0.15 vs. the industry median of 0.23, Theralase Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theralase Technologies's current Debt-to-Equity of 0.22 is 4.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Theralase Technologies and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theralase Technologies's current Debt-to-Equity is 0.22, which is 47% above median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.18 — trading 38.5% above its estimated fair value. The current Debt-to-Equity is 0.22, which is 47% above median its 10-year median of 0.15 and 4.3% below the Medical Devices & Instruments industry median of 0.23. Theralase Technologies' overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current Debt-to-Equity is 0.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theralase Technologies (TLTFF) Overvalued in 2026?
Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued.
The current stock price of $0.18 is trading 38.5% above its estimated GF Value™ of $0.13.
GuruFocus considers Theralase Technologies to be Significantly Overvalued.
Key valuation signals for TLTFF:
Debt-to-Equity: 0.22 (47% above median its 10-year median of 0.15)
GF Value™: $0.13 vs. price of $0.18 (38.5% above fair value)
Industry Position: 4.3% below the Medical Devices & Instruments median (#344 of 704)
No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
45GF Score
Get the complete analysis for TLTFF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLTFF has been successfully added to your 
